Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors

Publication Date: September 28, 2023
Last Updated: September 29, 2023

Treatment

I. General Recommendations for G1–G3 GEP-NETs

Recommendation 1.1

Selection of initial treatment options and sequencing of treatments following progression should consider patient and tumor characteristics such as hormone status, primary site, grade, extent and burden of disease, growth rate, comorbidities, and somatostatin receptor (SSTR) positivity, and should be discussed within a multidisciplinary team (MDT) when possible. (IC, B, L, S)
Notes:
  • While local therapy options are outside the scope of this systematic review and guideline, surgical cytoreduction (if feasible to achieve >70–90% reduction in tumor volume) or other types of liver-directed therapy (e.g., embolization) may be considered for patients with hepatic disease, and preferably should be discussed within the setting of an MDT.
  • In addition, while the use of somatostatin analogs (SSAs) for symptom management is outside the scope of these guidelines, SSAs are often used indefinitely in patients with functional NETs.
1048203

Overview

Title

Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors

Authoring Organization